Approval of etoricoxib is unacceptable! Authorised and reimbursed in France, despite an unfavourable risk-benefit balance

Noauthornameavailable

首页> 外文期刊>Prescrire international >Approval of etoricoxib is unacceptable! Authorised and reimbursed in France, despite an unfavourable risk-benefit balance

【24h】

Approval of etoricoxib is unacceptable! Authorised and reimbursed in France, despite an unfavourable risk-benefit balance

机译：依托昔布的批准是不可接受的！尽管存在不利的风险收益平衡，但仍在法国获得了授权和偿还

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In mid-March 2010, etoricoxib (Arcox-ia, Merck Sharp & Dohme-Chibret), a nonsteroidal antiinflammatory drug (NSAID) said to be "selective" for cyclo-oxygenase 2 (cox-2 inhibitor), was authorised in France for symptomatic treatment of osteoarthritis (1,2). It is available in hospital and community pharmacies, and "only" 35% of the treatment cost is reimbursed by the French national health insurance system (2).

机译：2010年3月中旬，法国批准了一种非甾体类抗炎药（NSAID）依托考昔（Arcox-ia，Merck Sharp＆Dohme-Chibret）对环氧化酶2（cox-2抑制剂）具有“选择性”。对症治疗骨关节炎（1,2）。它可以在医院和社区药店买到，法国国家健康保险系统仅补偿了治疗费用的35％（2）。

著录项

来源
《Prescrire international》 |2010年第108期|共1页
作者
Noauthornameavailable;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
专利

1. Approval of etoricoxib is unacceptable! Authorised and reimbursed in France, despite an unfavourable risk-benefit balance [J] . Noauthornameavailable Prescrire international . 2010,第108期

机译：依托昔布的批准是不可接受的！尽管存在不利的风险收益平衡，但仍在法国获得了授权和偿还
2. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018 [J] . Catherine Schuster Bruce, Petra Brhlikova, Joseph Heath, PLoS Medicine . 2019,第9期

机译：在两个欧洲药品管理局的加速批准途径中使用经过验证的和未经验证的替代终点：对2011-2018年授权产品的横断面研究
3. Views wanted on revised ‘Approval of establishments: guidance for local authority authorised officers’ and Q&A document [J] . Food Safety Briefing . 2016,第1116期

机译：希望对修订后的“机构批准：地方当局授权人员指南”和问答文件提出意见
4. Coil Velocities Error Reduction in the French Kibble Balance Experiment [C] . D Ziane, M Thomas, P Pinot, Conference on Precision Electromagnetic Measurements . 2018

机译：法国岩石平衡实验的线圈速度误差减少
5. Work and life in the balance: Ways of working and living among elite French, Norwegian, and American professionals. [D] . Schulz, Jeremy Markham. 2010

机译：平衡工作与生活：法国，挪威和美国的专业人士之间的工作和生活方式。
6. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018 [O] . Catherine Schuster Bruce, Petra Brhlikova, Joseph Heath, 2019

机译：在两个欧洲药品管理局的加速批准途径中使用经过验证的和未经验证的替代终点：对2011-2018年授权产品的横断面研究
7. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018 [O] . Catherine Schuster Bruce, Petra Brhlikova, Joseph Heath, 2019

机译：在两种欧洲药物机构中使用验证和非验证的代理端点加急批准途径：2011-2018授权产品的横断面研究
8. Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval: Guidance for Industry and Food and Drug Administration Staff. [R] . 2015

机译：为上市前批准的设备平衡上市前和上市后数据收集：工业和食品药品管理局工作人员指南。

Approval of etoricoxib is unacceptable! Authorised and reimbursed in France, despite an unfavourable risk-benefit balance

摘要

著录项

相似文献

相关主题

期刊订阅